Global Entecavir Market 2026–2030 supported by antiviral treatment demand

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Entecavir Market Projected To Become By 2030 Based On Its 2026 Valuation?

The entecavir market has experienced consistent expansion in recent years. It is anticipated to expand from $0.74 billion in 2025 to $0.77 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.2%. The historical increase can be attributed to several factors, including the high global prevalence of hepatitis B, the clinical effectiveness of nucleoside analogs, the broadening of antiviral treatment guidelines, enhanced hepatitis B diagnosis rates, and a rising global burden of liver disease.

The entecavir market is projected to experience consistent expansion over the upcoming years. Its value is anticipated to reach $0.9 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.1%. This growth during the projected timeframe stems from several factors, including an expanding chronic hepatitis B patient population, improved accessibility to antiviral treatments in developing economies, wider adoption of strategies for long-term viral suppression, an increase in public health initiatives targeting hepatitis, and a rising need for cost-effective generic medications. Key trends expected throughout this forecast period involve an uptick in the use of long-term antiviral therapies, a heightened emphasis on managing chronic hepatitis B, increasing consumer demand for oral antiviral drugs, broader availability of generic entecavir, and enhanced surveillance of viral load suppression.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21183&type=smp

Which Market Drivers Are Supporting The Expansion Of The Entecavir Market?

The increasing prevalence of hepatitis B is projected to drive the growth of the entecavir market moving forward. Hepatitis B is a viral infection that impacts the liver, leading to symptoms such as jaundice, fatigue, and abdominal pain, and can result in chronic liver disease or liver cancer if left untreated. The surge in hepatitis B cases is attributed to factors including unprotected sexual contact, sharing of needles, mother-to-child transmission during childbirth, and insufficient vaccination coverage in specific regions. Entecavir works to treat hepatitis B by inhibiting the replication of the hepatitis B virus (HBV) DNA, thereby reducing viral load and preventing liver damage. For instance, in August 2025, the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, non-Hispanic Asian/Pacific Islander individuals experienced a rate of newly reported chronic hepatitis B cases that was nearly 10 times higher than that of non-Hispanic White individuals. Therefore, the increasing prevalence of hepatitis B is a key driver for the entecavir market’s expansion.

What Segment Groups Are Identified Within The Entecavir Market?

The entecavir market covered in this report is segmented –

1) By Product Type: Tablets, Oral Solution

2) By Application: Hepatitis B Treatment, Liver Transplantation, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Tablets: Standard Dose Tablets, High Dose Tablets

2) By Oral Solution: Ready-to-Use Liquid Solution, Powder For Oral Solution

What Trends Are Advancing Progress In The Entecavir Market?

Major companies in the entecavir market are developing innovative drugs via clinical trials to improve efficacy and treatment outcomes for chronic hepatitis B patients, with the potential to reduce resistance and enhance long-term viral suppression. Clinical trials are research studies conducted to assess the safety, effectiveness, and potential side effects of novel treatments, drugs, or therapies in human participants. For instance, in October 2024, Aligos Therapeutics Inc., a US-based biotechnology company, is engaged in a phase 2 clinical trial for ALG-000184 for hepatitis B treatment. ALG-000184 is a type of therapy known as a capsid assembly modulator, operating by disrupting the formation of the capsid, the protective shell around a virus’s genetic material. The fourth phase of the study is currently evaluating the long-term effects of ALG-000184 (300 mg), either as a standalone treatment or alongside the approved antiviral entecavir, in patients with chronic hepatitis B. The combination of ALG-000184 and entecavir resulted in more significant reductions in viral load compared to entecavir alone, while ALG-000184 demonstrated comparable effectiveness, irrespective of its concurrent use with entecavir. The virus remained consistently suppressed throughout the study, encompassing both HBeAg-positive and HBeAg-negative patients.

Which Companies Hold Significant Positions In The Entecavir Market?

Major companies operating in the entecavir market are Bristol-Myers Squibb Company, GSK plc, Teva Pharmaceutical Industries Ltd., Qingfeng Pharmaceutical Group, Aurobindo Pharma Ltd., ScinoPharm Taiwan Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Inc., Zhejiang Huahai Pharmaceuticals Co. Ltd., Qianjin Group, Genix Pharma Ltd., Dawnrays Pharmaceutical Holidings Ltd., Zhejiang Ausun Pharmaceutical Co. Ltd., Hunan Warrant Chiral Pharmaceutical Co. Ltd., Camber Pharmaceuticals Inc., Century Pharmaceuticals Ltd., Aligos Therapeutics Inc. , HRV Global Life Sceince, Solco Healthcare LLC, Accela ChemBio Inc.

Read the full entecavir market report here:

https://www.thebusinessresearchcompany.com/report/entecavir-global-market-report

How Is The Entecavir Market Distributed Across Key Geographic Regions?

Asia-Pacific was the largest region in the entecavir market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the entecavir market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Entecavir Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21183&type=smp

Browse Through More Reports Similar to the Global Entecavir Market 2026, By The Business Research Company

Excavator Market Report 2026

https://www.thebusinessresearchcompany.com/report/excavator-global-market-report

Caviar Market Report 2026

https://www.thebusinessresearchcompany.com/report/caviar-global-market-report

Encoder Market Report 2026

https://www.thebusinessresearchcompany.com/report/encoder-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795